Amprius Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Amprius Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.01M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $24.17M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $9.05M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $4.41M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.77M | Mar 30, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.91M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $23.57M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $8.79M | Mar 20, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.26M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($18.33M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($14.68M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($5.65M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($4.33M) | Mar 30, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($44.02M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($44.67M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($36.78M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($17.33M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($9.90M) | Mar 30, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($46.65M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($46.26M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($38.71M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($18.04M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($10.62M) | Mar 30, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.43M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $7.34M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $3.68M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.03M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.45M | Mar 30, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.96M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $18.73M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $20.36M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $10.36M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.84M | Mar 30, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($31.13M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($33.35M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($25.55M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($13.88M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($8.02M) | Mar 30, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.40M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $3.21M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $17.55M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.48M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $609.0K | Mar 30, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $156.89M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $121.13M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $107.74M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $83.17M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $18.53M | Mar 30, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.08M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $51.65M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $47.94M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $10.14M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.67M | Mar 30, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.82M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $69.47M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $59.80M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $73.03M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $13.86M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.17M | Mar 30, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($218.36M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($174.33M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($129.66M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($92.89M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($75.40M) | Mar 30, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.47M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $55.16M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $45.76M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $69.70M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $11.49M | Mar 30, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 134.54M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 116.93M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 88.87M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 84.61M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 65.77M | Mar 30, 2023 |